Kenya says it will move ahead with AstraZeneca COVID-19 vaccine
That move will not deter Kenya, which says it expects to receive 24 million doses of the vaccine beginning this month, said Mercy Mwangangi, the chief administrative secretary at the ministry. "We are going to continue with AstraZeneca because we are doing our own sequencing and we are comfortable to move forward with it," she told Reuters.
Kenya is going ahead with its plan to inoculate its citizens against COVID-19 using a vaccine developed by AstraZeneca, a senior health ministry official said on Thursday, dismissing concerns over its efficacy.
South Africa paused the rollout of the vaccine developed by AstraZeneca and Oxford University following a small clinical trial that showed it offered minimal protection against mild to moderate illness from the 501Y.V2 variant dominant in the country. That move will not deter Kenya, which says it expects to receive 24 million doses of the vaccine beginning this month, said Mercy Mwangangi, the chief administrative secretary at the ministry.
"We are going to continue with AstraZeneca because we are doing our own sequencing and we are comfortable to move forward with it," she told Reuters. The World Heath Organisation had also issued an advisory on Wednesday telling countries to continue using the vaccine, Mwangangi said, which further supports the Kenyan government's position.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Kenya
- South Africa
- Oxford University
- Kenyan
- AstraZeneca
ALSO READ
Sanlam of South Africa to raise stake in Shriram Group insurance firms
South Africa all-rounder Marizanne Kapp found guilty of breaching ICC Code of Conduct
South African capital Pretoria second most crime-ridden city in the world: latest ranking
Tvesa Malik maintains momentum, lies T-7th in South Africa
Economic relations secretary in MEA to visit Rwanda, Uganda, Kenya